Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Tacrolimus in Primary Membranous Nephropathy
NCT05532111Unknown
- Sponsor
- Renji Hospital
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
01
Overview
Randomised, open-label trial of rituximab and tacrolimus + Wuzhi capsule in primary membranous nephropathy (PMN) (3 arms), sponsored by Renji Hospital. Primary endpoints: 24-hour urine protein quantification at 48 weeks and Serum albumin at 48 weeks. Status: unknown.
02
Drugs
rituximabtacrolimus + Wuzhi capsule
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT05532111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05532111.